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Background: Pharmacological thromboprophylaxis in the peri-operative period involves a trade-off between reduction
in venous thromboembolism (VTE) and an increase in bleeding. Baseline risks, in the absence of prophylaxis, for VTE
and bleeding are known to vary widely between urological procedures, but their magnitude is highly uncertain.
Systematic reviews and meta-analyses addressing baseline risks are uncommon, needed, and require methodological
innovation. In this article, we describe the rationale and methods for a series of systematic reviews of the risks of
symptomatic VTE and bleeding requiring reoperation in urological surgery.
Methods/design: We searched MEDLINE from January 1, 2000 until April 10, 2014 for observational studies reporting
on symptomatic VTE or bleeding after urological procedures. Additional studies known to experts and studies cited in
relevant review articles were added. Teams of two reviewers, independently assessed articles for eligibility, evaluated
risk of bias, and abstracted data. We derived best estimates of risk from the median estimates among studies rated
at the lowest risk of bias. The primary endpoints were 30-day post-operative risk estimates of symptomatic VTE and
bleeding requiring reoperation, stratified by procedure and patient risk factors.
Discussion: This series of systematic reviews will inform clinicians and patients regarding the trade-off between VTE
prevention and bleeding. Our work advances standards in systematic reviews of surgical complications, including
assessment of risk of bias, criteria for arriving at best estimates of risk (including modeling of timing of events and dealing
with suboptimal data reporting), dealing with subgroups at higher and lower risk of bias, and use of the Grading of
Recommendations Assessment, Development and Evaluation (GRADE) approach to rate certainty in estimates of risk.
The results will be incorporated in the upcoming European Association Urology Guideline on Thromboprophylaxis.
Systematic review registration: PROSPERO CRD42014010342.
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Introduction
Venous thromboembolism (VTE), which includes
deep vein thrombosis (DVT) and pulmonary embolism
(PE), represents a serious, and sometimes fatal, com-
plication of urological surgery. A systematic review
and meta-analysis including gastrointestinal, urological,
gynecological, and general surgical procedures has dem-
onstrated that pharmacological prophylaxis decreases
the risk of VTE in surgical patients by approximately
50% but increases the risk of post-operative major
bleeding by approximately 50% [1]. The decision to use
pharmacological prophylaxis therefore presents a trade-
off between a reduction in VTE and an increase in
bleeding.
The crucial issue in making this decision is the risk of
VTE and bleeding in those not receiving anticoagulants,
which we will refer to as ‘baseline risk’. Baseline risks,
in the absence of prophylaxis, for VTE and bleeding are
known to vary widely between urological procedures
[2], but their magnitude is highly uncertain. In patients
with a high risk of VTE and a low risk of bleeding, a
50% reduction in VTE represents substantial benefit
(for instance, from a baseline risk of 10% to 5%). In a
patient with a low baseline risk of bleeding (for instance,
from 0.2% to 0.3%), the balance of benefits and harms
clearly favors prophylaxis. The situation is reversed in
patients whose risk of VTE without anticoagulation is
low and whose bleeding risk is high. A small reduction
in VTE will not warrant the substantial increase in
bleeding. In patients whose risk of VTE and bleeding
are similar, the decision will depend on the relative
value patients place on avoiding VTE and avoiding
bleeding.
Thus, the decision regarding thromboprophylaxis is
critically dependent on the baseline risks of both VTE
and bleeding. Reliable estimates of these risks require
systematic summaries of the best available evidence, which
have thus far been unavailable [3]. Consequently, the
approach to thromboprophylaxis related to urological
surgery is an area with marked practice variation, both
within and between countries [4,5].
Our series of systematic reviews aims to fill this critical
gap in knowledge by addressing the risks of VTE and
bleeding requiring reoperation in patients undergoing
urological surgery but not receiving prophylaxis. Each
review summarizes the evidence regarding the fre-
quency of VTE and bleeding requiring reoperation for
procedures for diseases of the urinary tract and (male)
genital system. In this article, we outline the specific
methods used in our reviews and familiarize readers
with the methodology of systematic reviews and meta-
analysis of observational studies of complications and
their strengths and limitations.What are systematic reviews of baseline risk, and why are
they important but challenging to perform?
Systematic reviews are summaries of a body of evidence,
and meta-analysis is a quantitative, statistical method to
summarize the results. Preparing a systematic review
requires a number of decisions including determining the
focus; identifying, selecting, and critically appraising
the relevant primary studies; collecting and synthesizing
the relevant information; and drawing conclusions from the
evidence. Typically, investigators addressing questions of
therapy frame their research questions in accord with the
Patient, Intervention, Comparator and Outcome (PICO)
format with associated eligibility criteria [6]. This facilitates
the formulation of an answerable question from which
estimates of effect can be derived.
Conventional systematic reviews that compare one
treatment against another or against a non-treatment
control are common and the methods are well established
[6]. Systematic reviews and meta-analyses addressing
baseline risks (that is, risk in the absence of intervention,
in this case antithrombotic prophylaxis—of important
adverse outcomes, in this case VTE or bleeding requiring
reoperation) are sorely needed and require methodological
innovation [7]. The rates of events in the absence of
prophylaxis, required for estimation of benefits and risks,
can come only from systematic reviews of the relevant
studies. Nevertheless, few such systematic reviews have
been undertaken in any area of surgery [8] and none in
urology [3].
One reason for the dearth of such reviews is the multiple
challenges they present. First, indexing of observational
research is less well established than for randomized
controlled trials (RCTs), making it harder to identify
the relevant studies [9]. Second, surgical studies often
focus on disease-related outcomes (for instance, radical
prostatectomy papers usually report prostate cancer-
specific outcomes) but typically not on generic complica-
tions (including VTE and bleeding requiring reoperation).
Third, even when articles report risks of VTE and
bleeding, key information is often missing. Such infor-
mation includes the use of prophylaxis (usually varying
among patients), the timing of the events of interest, and
diagnostic criteria for the events of interest. Fourth, risk
of bias criteria, as well as criteria for overall certainty in
estimates [10], well established for reviews of therapeutic
trials are controversial in studies of baseline risk [7].
Fifth, the choice of studies to use for best estimates (e.g.,
synthesis from all studies or only from those at lowest
risk of bias) is uncertain [10]. Sixth, the incidence of
VTE has changed over time due to advances in surgical
technique and care (e.g., early mobilization) [11-13].
In these reviews, we address these challenges with the
goal of providing precedents for optimal methodology.
For the overall certainty in estimates of effect, we used
Tikkinen et al. Systematic Reviews 2014, 3:150 Page 3 of 8
http://www.systematicreviewsjournal.com/content/3/1/150the Grading of Recommendations Assessment, Deve-
lopment and Evaluation (GRADE) system, which has
provided detailed methodological guidance for system-
atic reviews [14], and initial standards for the assessment
of baseline risk [7].
Methods/design
Eligibility criteria
We included studies published in English language med-
ical journals that enrolled adult male or female patients
undergoing procedures for diseases of the urinary tract
and (male) genital system, including kidneys, ureters,
bladder, prostate, seminal vesicles, urethra, scrotum,
testicles, penis, and vagina (Additional files 1 and 2).
Reasoning that very small studies are likely to be pub-
lished only if they show anomalous results, we included
only studies with at least 50 adult patients per uro-
logical procedure to decrease risk of bias.
Although RCTs provide estimates of effect of treat-
ment with the lowest risk of bias, populations enrolled
are usually highly selected and RCTs are therefore, with
respect to estimating baseline risk, limited in terms of
generalizability [15,16]. Hence, observational studies of
unselected patients undergoing urological surgery are
likely to be the best source of estimates of VTE and
bleeding risk. Because baseline risk has changed over
time [11-13], we included studies that recruited all or a
majority of participants after the year 2000. Because the
complication estimates depend on the length of follow-
up, we included only studies that clearly defined the
time period of follow-up (up to 3 months).
Finally, we included only studies that reported at least
one absolute estimate of risk of the patient important
outcomes of interest (fatal PE, symptomatic PE, symptom-
atic DVT, symptomatic VTE, fatal bleeding, and bleeding
requiring reoperation). Absolute estimates include the
percentage (e.g., 1.0%), proportions (e.g., 0.02), natural
units or natural frequency (e.g., 3 in 1,000 patients), and
natural frequency per time (e.g., 3 in 1,000 patient years)
but do not include relative estimates, such as risk ratio or
odds ratio.
Literature search, study selection, application of eligibility
criteria, and data abstraction
We used two search strategies. First, we used the MED-
LINE database to search for potentially eligible articles
published from January 1, 2000 until April 10, 2014. A
combination of keyword and medical subject headings
search included the ‘urological procedures’ (more than
90 different urological procedures) term family combined
with the ‘thrombosis’ term family (Additional file 1) as
well as the ‘urological procedures’ term family combined
with the ‘bleeding’ term family and the prognosis sensitiv-
ity filter (Additional file 2). We included articles not in thesearch but known to the experts in the panel. Finally,
we identified further original articles by reviewing the
reference lists of included systematic reviews (none of
the systematic reviews summarized any of the outcomes
of interest of our series).
Two reviewers evaluated titles and abstracts from the
search and identified potentially eligible studies. We
obtained the full articles of these potentially eligible titles
and abstracts, and two reviewers assessed the full texts
to make final judgments regarding eligibility. Similarly,
two reviewers independently abstracted data including
outcomes, study characteristics, and risk of bias. A
clinician-methodologist adjudicator resolved disagree-
ments regarding eligibility or study characteristics. Finally,
we sent our consensus data extraction to the original
authors of each article for confirmation or correction.
When needed, we also asked authors to clarify details
regarding thromboprophylaxis, surgical technique (such
as pelvic lymph node dissection), as well as other missing
or unclear information.
Outcomes
Primary outcomes were the absolute risks of symptomatic
VTE and bleeding requiring reoperation (including
exploration and angioembolization). Secondary outcomes
were the absolute risks of fatal PE and fatal bleeding. All
outcomes were extracted and analyzed separately for each
procedure (see ‘Analysis’ section).
We also extracted the length of follow-up regarding
VTE and bleeding outcomes. When authors presented
the frequency of events at more than one time point, we
recorded the number of events up to 3 months and used
the absolute risk closest to 4 weeks (our primary outcome).
We did not collect data on events of questionable import-
ance to patients [17], in particular asymptomatic DVT,
changes in hemoglobin levels, or amount of estimated
blood loss during the operation. Transfusion rates were
not recorded primarily due to expected large differences in
clinical practice that would make it difficult to estimate the
trade-off of thrombosis and bleeding.
Final selection of eligible studies (risk of bias and outliers)
We assessed design features that could potentially bias
the estimates of VTE or bleeding risk. These include the
representativeness of the recruited patient population,
study type, losses to follow-up, explicitness of criteria for
VTE diagnosis, thromboprophylaxis documentation, and
data source (Table 1). We also collected information on
several other characteristics of the articles and their
study populations that may be predictive of VTE or
bleeding requiring reoperation (Table 2).
To assess applicability and representativeness of each
study and to assess heterogeneity between estimates, we
recorded the mean age of the study population and
Table 1 Design features considered for assessment of risk of bias
Domain Lower risk of bias Higher risk of bias
Sampling and representativeness
of the population
Consecutive patient recruitment or administrative
database with random sampling
Non-consecutive patient recruitment or administrative
database with non-random sampling
Study type International multicenter; multicenter in one
country; single center, not single surgeon
Single surgeon series
Source of information Data abstracted by investigators from patient charts Administrative database information
Thromboprophylaxis documentation Reporting of patients’ thromboprophylaxis No reporting of patients’ thromboprophylaxis
Diagnostic criteria Objective confirmation of symptomatic
venous thromboembolism
No objective confirmation of symptomatic
venous thromboembolism
Loss to follow-up Less than 20% loss to follow-up 20% or more loss to follow-up
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there were clear outliers, with atypical populations for
either of these factors, we excluded those studies.Analysis
Choosing best estimate
We used the median value of estimates from studies
with the lowest risk of bias to estimate baseline risk of
VTE and bleeding requiring reoperation. The reason we
chose the median as opposed to the pooled estimates
across studies is that even the largest studies are likely
to have factors idiosyncratic to that population and set-
ting that will influence risks of both thrombosis and
bleeding. There is little reason, given these idiosyncratic
factors, that larger studies should have more weight than
smaller studies. Under these circumstances, the medianTable 2 Characteristics assessed
Characteristics
Year of publication Patient recruitment (first and last year)
Source of samplinga Study typed
Country/countries Multinational (yes/no)
Urological procedure(s) Total number of patients
Gender distribution Age (mean/median/threshold)
Proportion of patients
with malignant disease
Use and extension of pelvic
lymph node dissection
Patient use of mechanical
thromboprophylaxisb
Patient use of anticoagulantse
Patient use of aspirin or
other antiplatelet drugsc
Patient use of both mechanical and aspirin/
anticoagulantsb,c,e
aEither retrospective case series, register/administrative database, or
prospective cohort study.
bIncluding antithrombosis stockings, intermittent pneumatic compression
devices, and foot-pumps.
cIncluding aspirin, clopidogrel, dipyridamole, prasugrel, ticagrelor, ticlopidine,
cilostazol, abciximab, eptifibatide, tirofiban, as well as thromboxane inhibitors,
thromboxane synthase inhibitors, thromboxane receptor antagonists,
and terutroban.
dEither single-surgeon series; single center, not single surgeon; multicenter in
one country; international multicenter.
eIncluding warfarin, low molecular weight heparin, low dose unfractioned
heparin, rivaroxaban, dabigatran, apixaban, fondaparinux, and idraparinux.is likely to provide better estimates of typical risk than is
the pooled estimate [18].
Modeling risk of VTE over time
We provided procedure-stratified estimates for both risk
of VTE and bleeding requiring reoperation in urological
surgery. We chose one and four-week time frames for
estimates of risks of thrombosis and bleeding because
these are feasible and frequently chosen time frames for,
respectively, shorter and longer term prophylaxis. For
studies that did not report VTE estimates using these
intervals, we modeled estimates—based on a literature
search (Additional file 3)—using large-scale population-
based studies (Amin, Beral, and Sweetland, personal
communications) [19,20] that have provided data regard-
ing the timing of post-surgical VTE. These results are
consistent with recent report using nationwide cystectomy
data from the United States [21]. To calculate absolute
risk of VTE by post-operative day, we calculated the mean
values (of VTE risk) from the available studies [19,20].
After assessing mean values for both studies and when
calculating the final model for VTE (Figures 1 and 2),
interpolated values were calculated using natural cubic
spline interpolation [22] and R data analysis language [23].Figure 1 Proportion of cumulative risk (%) of venous
thromboembolism by week since surgery during the first 12
post-operative weeks [19,20].
Figure 2 Proportion of cumulative risk (%) of venous
thromboembolism (VTE) and major bleeding by week since
surgery during the first 4 post-operative weeks [19,20,24].
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we used the thromboprophylaxis estimates from the
population-based US study [17] where 81.4% had used
either mechanical or pharmacological prophylaxis until
discharge (i.e., 81.4% used for median of 4.5 days) and
that 1.5% used from discharge (median discharge time
4.5 days) until median time of 35 days.
Modeling risk of bleeding over time
For studies that did not report their bleeding estimates
at 4 weeks, we modeled timing of bleeding using data
from the placebo arm of a large pragmatic RCT [24].
Ninety percent of the 30-day bleeding events happen
during the first week after surgery (and indeed, approxi-
mately 75% in the first 2 days), so that only a small pro-
portion of bleeding happens after the first post-operative
week (Figure 2). For studies that provided bleeding data
for a longer period than 30 days (but not more than
90 days), we therefore assumed a constant risk of bleed-
ing beyond the first post-operative week, so for example,
the day 30 rates were calculated at 80% of the rates at
day 90 (Figure 2).
Calculating risks
We extracted information from contemporary observa-
tional studies. However, one of the challenges of these
reviews relates to the decreasing incidence of VTE as
surgical techniques have improved and early mobilization
has become a standard of care [11-13]. Furthermore, in
the recent studies representing current rates of VTE,
patients often received prophylaxis. How then to estimate
baseline risk?
To adjust estimates of baseline risk for use of prophylaxis,
we used information from RCTs and meta-analyses of
RCTs about the relative risk of VTE and bleeding among
those who received prophylaxis [1,24-26]. Specifically, weused estimates from a meta-analysis of RCTs in urology,
general surgery, gynecology, and gastrointestinal surgery
that concluded that anticoagulants (such as low molecular
weight heparin, see Table 2) reduce the relative risk of VTE
by 50% [1] and increases the relative risk of major bleeding
by 50%. We used data from a meta-analysis of RCTs in
orthopedic surgery [26] for our estimate that direct oral
anticoagulants (Table 2) had similar effects on both VTE
and bleeding as low molecular weight heparin. Based
on a meta-analysis of RCTs in urology, general surgery,
gynecology, and gastrointestinal surgery, we estimated the
same efficacy of 50% VTE risk reduction for mechanical
prophylaxis (Table 2) [1]. However, we had low certainty
in the estimates for mechanical prophylaxis because
studies used surrogate outcomes, had very few events,
unblinded patients and assessors, and provided almost
no information on intermittent pneumatic compression.
Hence, we did not consider combination therapy as offer-
ing more protection than heparin alone when adjusting
for prophylaxis in the baseline risk estimates of VTE.
Finally, we assumed that aspirin (and other antiplatelet
drugs, see Table 2) reduces the relative risk of VTE by
30% and increases the relative risk of major bleeding by
20%, based on two large pragmatic surgical trials [24,25].
We then adjusted the reported risk by multiplying the
relative risk by the reported risk in the fraction of
patients who received prophylaxis. For instance, a study in
which all patients received anticoagulant prophylaxis for
4 weeks or 28 days (time point of our primary outcome)
showed a VTE risk of 1%, assuming that the relative risk
reduction with prophylaxis is approximately 50%, we in-
ferred that the included patients would have experienced
a 2% risk of VTE had they not received prophylaxis.
Similarly, in the same study, the bleeding risk was 3%,
because anticoagulant prophylaxis increases the risk of
bleeding by approximately 50%, we inferred a bleeding
risk of 2% without prophylaxis. Thromboprophylaxis
was often used for less than 4 weeks. In those circum-
stances, we estimated its impact using same rationale
but also considered the duration of thromboprophylaxis
by using our models (Figure 2).
If the study did not provide estimates of VTE but only
DVT and/or PE, we calculated the risk of VTE using the
following approach. We reviewed data from studies that
reported DVT, PE, and VTE totals and estimated the
overlap (i.e., patients with both DVT and PE) from these
studies. We then applied the degree of overlap to esti-
mate VTE frequency in trials that provided only separate
reports of DVT and/or PE.
Stratifying the risk of VTE according to patient risk factors
After assessing the baseline risk of VTE for each procedure,
we stratified the risk by patient risk factors. We conducted
a literature search addressing VTE risk factors in the
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intestinal surgery (Additional file 4). We developed a very
simple model for VTE risk based on the studies reporting
the most relevant and compelling evidence [27-35]. Risk
factors included 1) age more than 75 years, 2) obesity (body
mass index of 35 or more), and 3) VTE in a first degree
relative (parents, full siblings, or children)—all of these in-
crease the risk approximately twofold. The most important
risk factor was prior VTE, with risk ratio of approximately
4. We assumed that patients with any combination of two
or more risk factors had a risk ratio of 4. Using these risk
factors, we then categorized risk of VTE as low, medium
(risk ratio of 2), and high risk (risk ratio of 4).
To calculate estimates of absolute risks for these
groups, for each procedure, we estimated the proportion
of patients having each of the risk factors using eligible
studies. For both age and body mass index, we used the
median value and median SD for estimating risk and
assumed a normal distribution. We calculated the pro-
portion of those with history of VTE based on large
population-based study [35].
Our search did not reveal studies demonstrating convin-
cing and replicable risk factors for bleeding (Additional
file 5). Therefore, we did not stratify bleeding risk by
patient specific factors.
Case fatality
We also estimated case fatality rates for VTE and bleeding
requiring reoperation. For case fatality of VTE, we divided
the number of fatal PE by the number of symptomatic
VTE using studies that provided both estimates. Corres-
pondingly, for case fatality of bleeding requiring reopera-
tion, we divided the number of fatal bleeding by the
number of bleeding requiring reoperation.
Discussion
Our methods meet the criteria for rigorous systematic
reviews. We specified explicit eligibility criteria, conducted
comprehensive searches (not only for baseline risk but
also for timing of complications and patient risk factors),
and assessed risk of bias using criteria specific to this
review. In addition, teams of two reviewers independently
assessed eligibility and risk of bias and extracted data, a
third reviewer adjudicated discrepancies, and we sent
our consensus of data extraction to the original authors
of each article for confirmation or correction. We con-
sidered, for the first time in urology, risk of VTE and
bleeding separately for each procedure including surgi-
cal technique (for instance, open vs. robotic and radical
vs. partial). We took into account length of follow-up,
use of thromboprophylaxis, and patient risk factors.
Our reviews have limitations. Our analyses reflect pub-
lished data and we cannot completely exclude publication
bias. Because reporting of surgical complications is sporadicand ad hoc, it is possible that literature is biased towards
underreporting of events. This is especially true regarding
single-surgeon series: individual surgeons experiencing high
rates of complications are unlikely to publish their results.
Secondly, due to poor reporting standards (both indexing
and abstract information), our search likely missed some
relevant studies.
We have carefully addressed the many challenges
involved in generating best estimates of risk of VTE and
bleeding in the absence of antithrombotic prophylaxis in
patients undergoing urological surgery. Clinicians can
therefore look to the systematic reviews in this series as
providing the best current estimates of the risk of both
symptomatic VTE and bleeding requiring reoperation in
urological procedures. Guideline panels will find these
estimates helpful when formulating recommendations for
VTE prophylaxis in urological surgery. Moreover, these
reviews provide guidance for best practices in systematic
reviews of observational data—particularly with regard to
surgical complications.
Additional files
Additional file 1: Search history for baseline risk of VTE.
Additional file 2: Search history for baseline risk of major bleeding/
bleeding requiring reoperation.
Additional file 3: Search history for modeling of risk for venous
thromboembolism after surgery.
Additional file 4: Search history for patient related risk factors of
venous thromboembolism after surgery.
Additional file 5: Search history for patient related risk factors of
major bleeding/bleeding requiring reoperation after surgery.
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